Skip Ribbon Commands
Skip to main content

CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation)

Atrial fibrillation is a common arrhythmia seen in clinical practice and is associated with an increased risk of stroke and death. In recent years, percutaneous catheter-based ablation procedures have been developed to modify atrial tissue and thereby treat or eliminate atrial fibrillation.
​​
Dr. Brian DeVille of Arrhythmia Management in association with Heart Hospital Baylor Plano is participating in the landmark CABANA trial; a multicenter randomized trial that assesses if catheter ablation for eliminating atrial fibrillation is superior to current therapy with either rate control or rhythm control drugs. Reducing total mortality is the primary endpoint and decreasing total mortality, disabling stroke, serious bleeding, and cardiac arrest are secondary endpoints in patients with untreated or incompletely treated atrial fibrillation warranting therapy. Other important endpoints that will be assessed by the trial include stroke, quality of life, and health care costs.

Patients eligible for the study are individuals with documented episodes of atrial fibrillation that last at least one hour and who have had two or more episodes over a four-month period. The patients must also be 65 years or older or younger than 65 providing they have a history of high blood pressure, diabetes, heart failure, or prior stroke. This is a multi-center study that will recruit 3,000 patients from 140 centers in North America, Asia, Europe and Australia. Patients will be enrolled for three years and followed for a minimum of two years. The CABANA trial is a pivotal study that will define the best treatment options for atrial fibrillation. For information about participating in the CABANA trial, call 1-800-4BAYLOR or visit BaylorHealth.com/advancingmedicine

  • ICY
  • reMARQable
  • Attain​
  • Versatile (V-Drive)
  • Stop AF PAS